Details for Patent: 12,016,927
✉ Email this page to a colleague
Which drugs does patent 12,016,927 protect, and when does it expire?
Patent 12,016,927 protects ABILIFY ASIMTUFII and is included in one NDA.
This patent has sixty-six patent family members in thirty-one countries.
Recent additions to Drugs Protected by US Patent 12,016,927
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Req. | Patent Expiration | Usecode | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Otsuka | ABILIFY ASIMTUFII | aripiprazole | SUSPENSION, EXTENDED RELEASE | 217006 | Apr 27, 2023 | RX | Yes | 12,016,927 | Y | ⤷ Subscribe | U-3245 | MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER | ||
| Otsuka | ABILIFY ASIMTUFII | aripiprazole | SUSPENSION, EXTENDED RELEASE | 217006 | Apr 27, 2023 | RX | Yes | 12,016,927 | Y | ⤷ Subscribe | U-543 | TREATMENT OF SCHIZOPHRENIA | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Req. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
Drugs Protected by US Patent 12,016,927
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Otsuka | ABILIFY ASIMTUFII | aripiprazole | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 217006-001 | Apr 27, 2023 | RX | Yes | No | 12,016,927 | ⤷ Subscribe | Y | MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER | ⤷ Subscribe | |||
| Otsuka | ABILIFY ASIMTUFII | aripiprazole | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 217006-001 | Apr 27, 2023 | RX | Yes | No | 12,016,927 | ⤷ Subscribe | Y | TREATMENT OF SCHIZOPHRENIA | ⤷ Subscribe | |||
| Otsuka | ABILIFY ASIMTUFII | aripiprazole | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 217006-002 | Apr 27, 2023 | RX | Yes | Yes | 12,016,927 | ⤷ Subscribe | Y | TREATMENT OF SCHIZOPHRENIA | ⤷ Subscribe | |||
| Otsuka | ABILIFY ASIMTUFII | aripiprazole | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 217006-002 | Apr 27, 2023 | RX | Yes | Yes | 12,016,927 | ⤷ Subscribe | Y | MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,016,927
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 090776 | ⤷ Subscribe | |||
| Argentina | 126033 | ⤷ Subscribe | |||
| Australia | 2013253374 | ⤷ Subscribe | |||
| Australia | 2017228608 | ⤷ Subscribe | |||
| Australia | 2019200060 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
